GSE209535 NDRG1 overexpression 1 v 0 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE209535_NDRG1 overexpression_1_v_0_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE209535_NDRG1 overexpression_1_v_0_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE209535_NDRG1 overexpression_1_v_0_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE209535_NDRG1 overexpression_1_v_0_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

microtubule associated protein 7

Gene

eukaryotic translation initiation factor 1A Y-linked

Gene

lysine demethylase 5D

Gene

cytochrome P450 family 1 subfamily B member 1

Gene

amphiregulin

Gene

carbonic anhydrase 12

Gene

aldehyde dehydrogenase 1 family member A1

Gene

3-hydroxy-3-methylglutaryl-CoA synthase 1

Gene

adipogenesis regulatory factor

Gene

stearoyl-CoA desaturase

  • Gene

    microtubule associated protein 7


  • Gene

    eukaryotic translation initiation factor 1A Y-linked


  • Gene

    lysine demethylase 5D


  • Gene

    cytochrome P450 family 1 subfamily B member 1



  • Gene

    carbonic anhydrase 12


  • Gene

    aldehyde dehydrogenase 1 family member A1


  • Gene

    3-hydroxy-3-methylglutaryl-CoA synthase 1


  • Gene

    adipogenesis regulatory factor


  • Gene

    stearoyl-CoA desaturase

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.